WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=MesenchymalStemCell]> and/or	0.005999147672446282
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Vehicle]> with 0.5 μl of	0.005999117478451538
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=Rostral]> injections 1 mm	0.004999291114546214
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Vehicle]> of OEC suspension or	0.004999136236066795
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=CyclosporineA]> received 5 mg of	0.0049989604695893815
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> with or without 400,000	0.004998799586954582
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=DosageExtracorporal]> with or without	0.004998692313260129
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> alone or with	0.0039996697109809754
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and another 0.5 mm	0.003999182887359184
WBO <EntityType [entityTypeName=BrainDerivedNeurotrophicFactor], EntityType [entityTypeName=InfusionDelivery]> or vehicle was	0.003999176383286006
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=Vehicle]> , Schwann cells or	0.0029997173625924854
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> of a suspension of	0.0029995496955010094
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Vehicle]> with 0.5 µl of	0.0029993465262989384
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and two 1 mm	0.0029992967262761046
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> of either an	0.0029992870335914515
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Vehicle]> at identical volumes of	0.0020000244855199146
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and two just	0.0019999394964658698
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> , 1 mm	0.0019998516011805693
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> , seven received non-modified	0.001999790107960225
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> , 1.5–2mm	0.001999754520218078
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> OECs by intraspinal	0.0019996874394552066
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=InjectionDelivery]> was administered by intraspinal	0.001999657331044334
WBO <EntityType [entityTypeName=Direction], EntityType [entityTypeName=Direction]> , central and	0.00199961484279194
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and another two	0.0019995824467472275
WBO <EntityType [entityTypeName=Tissue], EntityType [entityTypeName=DeliveryMethod]> or ALP were carefully	0.0019994889632488637
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=Rostral]> were injected 1 mm	9.999768477632054E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> BMSCs by intraspinal	9.997795717738222E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> Ringer solution were	9.9971828715849E-4
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and 1 mm	3.903452276664185E-7
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Caudal]> into the rostral and	-5.081463353491005E-7
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> cells) suspension was	-9.997167875820379E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> ) based on	-9.99719886709185E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> ) based on injected	-9.997199866811884E-4
WBO <EntityType [entityTypeName=Caudal], EntityType [entityTypeName=Vehicle]> spinal cord stumps with	-9.997449799957073E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=DosageExtracorporal]> containing OECs (	-9.997491789338507E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> /kg,	-9.997502786586595E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=DosageExtracorporal]> at a concentration of	-9.997560772276569E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=InjectionDelivery]> remained confined to the	-9.997852705341784E-4
WBO <EntityType [entityTypeName=SurgeryTreatment], EntityType [entityTypeName=Caudal]> . The rostral and	-9.997864702773398E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Rostral]> injection, and the	-9.997881699159497E-4
WBO <EntityType [entityTypeName=Cell], EntityType [entityTypeName=SchwannCell]> nerve Schwann cells (	-9.997949684992834E-4
WBO <EntityType [entityTypeName=SchwannCell], EntityType [entityTypeName=Vehicle]> , or control	-9.99795768335656E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Caudal]> sites rostral and	-9.997958683152478E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Rostral]> were applied 1 mm	-9.99801067267787E-4
WBO <EntityType [entityTypeName=Tissue], EntityType [entityTypeName=DeliveryMethod]> mucosa were gently	-9.998030668721162E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=MesenchymalStemCell]> Primary cultures of	-9.998052664414974E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> ) and 2 ml	-9.998103654618557E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=Vehicle]> OEC-M and 1 ml	-9.998103654618557E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=Vehicle]> and 1 ml	-9.998103654618557E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> group and high-dose	-9.99810465442907E-4
WBO <EntityType [entityTypeName=DosageExtracorporal], EntityType [entityTypeName=DosageExtracorporal]> of cyclosporine and	-9.998573576579216E-4
WBO <EntityType [entityTypeName=Cell], EntityType [entityTypeName=InjectionDelivery]> ) suspension was	-9.998593573748316E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=InjectionDelivery]> (+) was	-9.998629568753483E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> ; (3)	-9.998838542315631E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=Rostral]> injections were placed	-9.99884954104515E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=Vehicle]> , non-transduced OEG or	-9.998853540586156E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=MesenchymalStemCell]> and 3 × 105	-9.998864539332174E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> (3 × 105	-9.998865539218775E-4
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> to 4 mm	-9.999261502172748E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=InjectionDelivery]> - 10S was	-9.99952448623412E-4
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=Direction]> were made at the	-9.999648481118606E-4
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=Rostral]> treatment on the SPNs	-9.999877475713125E-4
WBO <EntityType [entityTypeName=Cell], EntityType [entityTypeName=Rostral]> injections at 1 mm	-9.999900475460013E-4
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Rostral]> at 1 mm	-9.999901475450208E-4
WBO <EntityType [entityTypeName=Rostral], EntityType [entityTypeName=Caudal]> and 0.5 mm	-0.0019994953599833942
WBO <EntityType [entityTypeName=Vehicle], EntityType [entityTypeName=Vehicle]> alone (group	-0.001999843001142088
WBO <EntityType [entityTypeName=InjectionDelivery], EntityType [entityTypeName=Caudal]> 1 mm rostral and	-0.0019998518000345967
WBO <EntityType [entityTypeName=OlfactoryEnsheathingGliaCell], EntityType [entityTypeName=OlfactoryEnsheathingGliaCell]> and ONFs The	-0.001999860702382742
WBO <EntityType [entityTypeName=Cell], EntityType [entityTypeName=Cell]> The OECs and	-0.0029996017833903627
WBO <EntityType [entityTypeName=Tissue], EntityType [entityTypeName=DeliveryMethod]> or RLP tissue was	-0.003999604614203928
